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Abstract: In addition to the prototypic amyloid-b (Ab) pep-
tides Ab1–40 and Ab1–42, several Ab variants differing in their
amino and carboxy termini have been described. Synthetic
availability of an Ab variant is often the key to study its role
under physiological or pathological conditions. Herein, we
report a protocol for the efficient solid-phase peptide syn-
thesis of the N-terminally elongated Ab-peptides Ab¢3–38,
Ab¢3–40, and Ab¢3–42. Biophysical characterization by NMR
spectroscopy, CD spectroscopy, an aggregation assay, and
electron microscopy revealed that all three peptides were
prone to aggregation into amyloid fibrils. Immunoprecipita-
tion, followed by mass spectrometry, indicated that Ab¢3–38
and Ab¢3–40 are generated by transfected cells even in the
presence of a tripartite b-site amyloid precursor protein
cleaving enzyme 1 (BACE1) inhibitor. The elongated Ab pep-
tides starting at Val(¢3) can be separated from N-terminally-
truncated Ab forms by high-resolution isoelectric-focusing
techniques, despite virtually identical isoelectric points. The
synthetic Ab variants and the methods presented here are
providing tools to advance our understanding of the poten-
tial roles of N-terminally elongated Ab variants in Alzhei-
mer’s disease.
Introduction
Brain deposition of amyloid-b (Ab) peptides into neuritic
plaques is one of the classical neuropathological hallmarks of
Alzheimer’s disease (AD).[1] Ab peptides are generated under
physiological conditions by consecutive proteolytic cleavages
of the amyloid precursor protein (APP) by so-called b- and g-
secretases.[2] A well-known “non-amyloidogenic” APP process-
ing pathway involves cleavage within the Ab-sequence by a-
secretase.[3,4] Recently, further cellular APP processing pathways
involving h- and d-secretases, both cleaving full length APP N-
terminally to the b-secretase cleavage site, were reported.[5,6]
A considerable number of Ab variants differing in the exact
length of their amino and carboxy termini have been identified
in amyloid plaques,[7] in blood plasma,[8] and in the cerebrospi-
nal fluid (CSF).[9] In particular, Ab peptides ending at Ala(42)
(Ab42)
[10,11] and N-terminally truncated Ab peptides starting
with Glu(3), post-translationally cyclized into pyroglutamic acid
(N3pE),[12,13] or Phe(4) are highly abundant in the parenchymal
amyloid plaques in AD brain.[1] Well documented and widely
accepted biomarkers of cerebral Ab accumulation, which have
been incorporated into updated recommendations on diag-
nostic guidelines for Alzheimer’s disease, are increased tracer
signals on amyloid positron emission tomography (PET) imag-
ing and low levels of soluble Ab42 in the CSF.
[14] Recently, the
concentration ratio of the Ab peptides APP669–711/Ab1–42 in
blood plasma, as measured by immunoprecipitation followed
by mass spectrometry, was reported to be strongly and posi-
tively correlated with amyloid PET.[15] A validated and reliable
biochemical AD-surrogate biomarker in blood would be highly
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advantageous for clinical routine, in particular since blood is
much easier accessible than the CSF. The peptide APP669–711
(APP770 numbering) refers to an Ab40 peptide starting 3 resi-
dues upstream of the “classical” Ab sequence, that begins with
Asp(1). We thus refer to this peptide as Ab¢3–40. The source of
Ab¢3–40 in blood is currently unknown, neither is its role under
physiological or pathological conditions. In cell culture super-
natants of the Chinese hamster ovary cell line 7PA2, transfect-
ed with mutant APP751 (Val–Phe 717), Ab¢3–40 was reported to
be increased on inhibition of the b-site APP-cleaving enzyme
1 (BACE1), suggesting that it results from an APP-processing
pathway independent of BACE1.[16] Herein, we describe the
solid-phase synthesis of the three N-terminally elongated Ab
peptides Ab¢3–38 (1), Ab¢3–40 (2), and Ab¢3–42 (3) (Table 1). We
also present a comprehensive biophysical characterization of
the N-terminally elongated peptides addressing peptide con-
formations and their aggregation into b-sheet-enriched amy-
loid fibrils in vitro. Moreover, we have identified Ab¢3–40 (2) to
represent one of the BACE-inhibitor-resistant Ab peptides pro-
duced from SH-SY5Y cells transfected with wild-type human
APP.
Results and Discussion
Several Ab variants have already been synthesized by various
techniques including solid-phase peptide synthesis (SPPS).[17,18]
The synthesis of Ab peptides, elongated by three residues at
the N-terminus, was achieved by automated solid-phase pep-
tide synthesis on an ABI 433A peptide synthesizer. Attempts to
obtain the Ab peptides 1–3 using a Wang resin on polystyrene
as a solid support, the standard FastMoc protocol from ABI,
and the O-acyl-isopeptide method failed.[17c–e] However, when
using a Wang resin on polyethylene glycol as a solid support
(0.1 mmol scale)[17b] in combination with a 10-fold excess of
Fmoc-protected amino acids (1 mmol), extended coupling
times (35 min or 50 min),[17b,20] and a twofold coupling for the
amino acids Ser(26) and Ala(30), the Ab peptides 1–3 were ob-
tained as major products (see Experimental Section). After pu-
rification by preparative HPLC, the Ab peptides 1–3 were iso-
lated in good yields (Table 1) and high purities (Table 2). The
characterization of 1–3 was achieved by high-resolution ESI-MS
(Table 2, Supporting Information).
For Ab¢3–38 (1) and Ab¢3–40 (2) the isolation after SPPS and
purification by preparative HPLC was achieved without any dif-
ficulty in a standard manner. However, the behavior of Ab¢3–42
(3) was very different. Some of the Ab¢3–42 (3) precipitated al-
ready during cleavage of the crude peptide from the PEG
resin, indicating that more of the cleavage reagent (TFA/1,2-
ethanedithiol/H2O/iPr3Si-H, 95:2:2:1) was required in order to
remove the peptide completely from the resin. Moreover, for
HPLC the standard polar gradient proved to be unsuitable.
With water as major component of the mobile phase, Ab¢3–42
(3) formed undefined oligomers that were eluting from the
column over a long period of time. Using acetonitrile as major
component in the HPLC solvent mixture for the purification
process, Ab¢3–42 (3) eluted from the column as a single peak
after about 3 min (Table 2). This procedure provided the N-ter-
minally elongated Ab peptides 1–3 in quantities of 15–30 mg
(see Experimental Section). Since the Ab peptides can misfold
and give rise to aggregates leading to oligomers and fibrils,
they are considered as peptides which are difficult to synthe-
size.[19] Therefore, the present synthesis of the Ab peptides 1–3
is remarkable with respect to scale and purity.
Several N-terminally elongated peptides including Ab¢3–38
(APP669–709), Ab¢3–39 (APP669–710) and Ab¢3–40 (APP669–711)
have been identified in human EDTA-blood plasma.[15] Further-
more, the ratio of Ab¢3–40 to Ab1–42 (APP669–711/Ab1–42) was
proposed as a novel peripheral surrogate biomarker of amyloid
deposition in the brain of AD patients.[15b] So far, nothing is
known about the structure of the Ab¢3–40 peptide (2) and its
potential to form insoluble aggregates. Having the N-terminal-
ly elongated Ab peptides 1–3 available by synthesis, we first
sought to obtain insight into the overall structure of Ab¢3–40 (2)
in solution by pulse-field gradient (PFG)-NMR experiments,
which quantify the diffusion of molecules and thus allow quan-
tification of their hydrodynamic radius (Table 3). Application of
PFG-NMR measurements to 70 mm of freshly dissolved Ab¢3–40
(2) resulted in a translational diffusion coefficient of 5.9Õ
10¢7 cm2 s¢1.[21] On the basis of this diffusion coefficient and
the Stokes–Einstein equation, a hydrodynamic radius Rh of
1.91 nm was calculated for Ab¢3–40 (2). This hydrodynamic
radius is consistent with an elongated, disordered peptide of
Table 1. Amino acid sequence and yields of the N-terminally elongated Ab peptides Ab¢3–38, Ab¢3–40, and Ab¢3–42 (1–3).
Ab Sequence Isolated yield [%][a]
1 ¢3–38 H-VKMD1AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGG38-OH 5.7
2 ¢3–40 H-VKMD1AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV40-OH 4.7
3 ¢3–42 H-VKMD1AEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA42-OH 3.3
[a] Yields after purification of the crude products by preparative HPLC.
Table 2. Analytical data for the Ab peptides 1–3.
Retention time [min][a] Purity [%][b] M [calcd][c] M [found][d]
1 20.6[e] 98.0 4487.2155 4487.2167
2 18.4[e] 97.4 4685.3523 4685.3490
3 2.92[f] 99.9 4869.4735 4869.4698
[a] Retention time on analytical HPLC; column: Vydac 208TP104 (reversed
phase C8, 4.6Õ250 mm); flow rate: 1.0 mLmin
¢1; eluent A: H2O with 0.1%
TFA; eluent B: MeCN with 0.1% TFA. [b] Purity based on analysis by an
evaporative light-scattering detector. [c] Calculated monoisotopic mass.
[d] Monoisotopic mass reconstructed by deconvolution of the ESI mass
spectra. [e] Gradient from 20% to 50% of eluent B in 30 min. [f] Gradient
from 60% to 90% of eluent B in 30 min.
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43 amino acids.[22] Next, we investigated the two N-terminally
elongated peptides, which end either at residue 38 (Ab¢3–38)
(1) or 42 (Ab¢3–42) (3). Determination of the translational diffu-
sion coefficients followed by calculation of Rh, resulted in
values of 1.79 and 1.60 nm for Ab¢3–38 (1) and Ab¢3–42 (3), re-
spectively. Despite the longer sequence, the Rh of Ab¢3–42 (3)
was slightly smaller than that of Ab¢3–38 (1) and Ab¢3–40 (2). This
result suggests that Ab¢3–42 (3) is more compact than the pep-
tides 1 and 2.
It is known that Ab1–40 and Ab1–42 monomers in aqueous so-
lution are mainly unstructured,[23,24] but exhibit a tendency to
adopt b-hairpin conformations.[24,25] To gain insight into the
monomeric structure of the N-terminally elongated Ab pep-
tides at single residue level, 2D homonuclear proton NMR
spectra were measured for freshly prepared Ab¢3–38 (1), Ab¢3–40
(2), and Ab¢3–42 (3) samples (ca. 70 mm, pH 7.4 buffered with
20 mm sodium phosphate). The sequence-specific proton-reso-
nance assignments of all three peptides were obtained
through the analysis of two-dimensional TOCSY and NOESY
spectra. We then compared the TOCSY spectra of the three
peptides 1–3 (Figure 1). These peptides, which all start at posi-
tion ¢3 and only differ at the C-terminus, show a nearly com-
plete overlay of their TOCSY spectra, with differences being re-
stricted to the immediate C-terminal regions (Figure 1B). In
contrast, the chemical shifts of Ab¢3–40 (2) and Ab1–40 revealed
some interesting differences beyond the presence of the four
additional peaks, which correspond to Lys(¢2), Met(¢1),
Asp(1), and Ala(2) (Figure 1A). In particular, the cross peaks of
residues Glu(3), Phe(4), Arg(5), and to a lesser extent Asp(7),
Gly(9), and Tyr(10) showed perturbations in their HN chemical
shifts. Moreover, the chemical-shift deviations were not limited
to the N-terminal region of Ab, but also included residue
Ser(26), which points to a long-range effect of the N-terminal
elongation. Taken together, the NMR data demonstrate that N-
terminally elongated Ab peptides are disordered in solution
and that N-terminal elongation influences the backbone con-
formation of Ab particularly in, but not limited to, its N-termi-
nal region.
The N-terminal region of Ab peptides is highly important for
its aggregation and toxicity.[26–28] We therefore decided to in-
vestigate the impact of N-terminal elongation on the aggrega-
tion behavior of Ab peptides using a set of biophysical tech-
niques. First, we performed an NMR-based monomer-con-
sumption assay to quantify the time-dependent conversion of
Ab monomers to NMR-invisible aggregates. The 1D proton
NMR spectra of Ab samples were measured before and after
Table 3. Translational diffusion coefficients and hydrodynamic radii of Ab
peptide variants obtained through PFG-NMR diffusion measurements.
Dt [10




Ab¢3–38 (1) 6.30.2 1.790.07
Ab¢3–40 (2) 5.90.3 1.910.08
Ab¢3–42 (3) 7.00.2 1.600.04
Ab1–42 6.60.1 1.710.03
[a] The hydrodynamic radius of dioxane was used for viscosity correction.
[b] DSS=4,4-Dimethyl-4-silapentane-1-sulfonic acid. [c] Translational diffu-
sion coefficients were obtained after gradient calibration as described
previously.[21] [d] The errors represent 95% confidence intervals.
Figure 1. Effects of N-terminal elongation on the structure of Ab peptides as
revealed by 2D proton-proton NMR spectroscopy. A) Superimposed TOCSY
spectra of Ab1–40 (purple) and Ab¢3–40 (2) (red) along with cross-peak assign-
ments. Some additional peaks are observed in the spectrum of Ab¢3–40 (2)
(M-1, K-2, D1, A2). Peaks with strong displacement are highlighted by arrows
(E3, F4, R5). B) Superposition of the TOCSY spectra of Ab¢3–38 (1) (cyan),
Ab¢3–40 (2) (red), and Ab¢3–42 (3) (green) show a nearly perfect fit except in
their differing C-terminal region. C) Combined HN and HA chemical-shift dif-
ference between Ab1–40 and Ab¢3–40 (2) indicate local conformational
changes in the N-terminal region as well as a long-range effect on residue
Ser(26) (highlighted by asterisk).
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24 h of incubation in aggregation-prone conditions (37 8C,
gentle stirring). The concentration of monomeric Ab was esti-
mated from the NMR signal intensity using DSS (4,4-dimethyl-
4-silapentane-1-sulfonic acid) as internal reference. Immediate-
ly after dissolving and before incubation, the monomeric con-
centrations of Ab¢3–38 (1) and Ab¢3–40 (2), as estimated by NMR
spectroscopy, were very close to their nominal concentration,
indicating that they were almost fully solubilized (Figure 2). On
the other hand, the initial monomeric concentration of Ab¢3–42
(3) was approximately only 60% of its nominal concentration,
reflecting its limited solubility. After 24 h of incubation, the
monomer concentrations of Ab¢3–38 (1), Ab¢3–40 (2), Ab¢3–42 (3),
and Ab1–42 decreased to 11, 6, 15, and 6% of the initial nominal
concentrations, respectively (Figure 2). Thus, the N-terminally
elongated Ab peptides (1–3) rapidly assemble into high-molec-
ular-weight aggregates. Further comparison of the data for
Ab¢3–42 (3) and Ab1–42 showed that N-terminal elongation re-
sulted in a decreased Ab peptide monomer loss.
Next, we monitored if the secondary structures of the N-ter-
minally elongated Ab peptides (1–3) were altered during ag-
gregation. To this end, we used UV circular dichroism (Fig-
ure 3A). Before aggregation, Ab¢3–38 (1), Ab¢3–40 (2), Ab¢3–42 (3),
and Ab1–42 showed CD spectra with negative minima around
200 nm, which are characteristic for disordered polypeptide
conformations. In agreement with their incomplete solubiliza-
tion, evidenced by NMR spectroscopy (see above), the CD
spectra of Ab¢3–42 (3) and Ab1–42 had less negative ellipticities
at 200 nm. In addition, larger negative ellipticities were ob-
served around 220 nm, indicating the copresence of b-sheet-
rich aggregates in these samples. After 24 h of aggregation, all
four Ab peptide variants exhibited structural conversion from
random-coil to b-sheet (Figure 3B). The spectra of the aggre-
gated Ab1–42, and to a lesser degree Ab¢3–42 (3), contained
strong negative peaks around 217–219 nm, indicative of ex-
tended b-sheet segments. In contrast, the CD spectra of aggre-
gated Ab¢3–38 (1), and in particular Ab¢3–40 (2), showed signifi-
cant red shifts of this negative peak to about 222–224 nm,
suggesting that the aggregated species of these two Ab var-
iants may contain some type-II b-turn structures.
CD spectroscopy showed that the N-terminally elongated
Ab peptides (1–3) aggregate into b-sheet-rich structures. To
test if the formed aggregates are amyloid fibrils, we used the
amyloid-specific dye thioflavin T (ThT). The fluorescence inten-
sity of ThT is low when in solution or bound to less stable ag-
gregation intermediates, but is very high when bound to amy-
loid fibrils.[29] All three N-terminally elongated Ab peptide var-
iants exhibited a high rate and amount of aggregation
(Figure 4). After only one hour of incubation in aggregation-
prone conditions a significant rise in ThT fluorescence emission
intensity was observed for Ab¢3–38 (1), Ab¢3–40 (2), and Ab¢3–42
(3). In case of Ab1–42, sizeable ThT fluorescence intensity was al-
ready present in freshly prepared samples, indicating the in-
complete solubilization of preformed aggregates. To further in-
vestigate the ability of N-terminally elongated Ab peptides to
form amyloid fibrils, we examined the aggregated samples by
electron microscopy. The peptide Ab¢3–38 (1) formed fibrillar ag-
gregates of various morphologies (Figure 5). The majority of
Figure 2. Ab peptide monomer consumption during aggregation as evaluat-
ed by NMR spectroscopy. The nominal Ab peptide concentration is displayed
by filled circles. After 1 day of aggregation, the monomer concentration, de-
termined by NMR spectroscopy, significantly decreased in all Ab peptide var-
iants of this study. The relative errors in peptide concentration estimated
from duplicate NMR measurements are smaller than 1%.
Figure 3. UV-CD spectra of Ab peptides A) before and B) after aggregation.
A) The freshly prepared Ab peptide solutions showed predominantly coil-
like structures with a negative band around 200 nm. B) After aggregation,
a prominent coil-to-beta transition occurred in all studied Ab peptide var-
iants. The CD intensity difference in B) was partially caused by precipitation
of large Ab peptide aggregates during the experiments.
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the aggregates were twisted pairs of long fibrils, while also
some straight fibrils with or without lateral association were
observed. In the Ab¢3–40 (2) sample, fewer but longer fibrils
were observed and they were predominantly twisted. In con-
trast, both Ab¢3–42 (3) and Ab1–42 formed a mixture of short
curved protofibrils and long twisted fibrils (Figure 5).
In order to evaluate the effect of N-terminal elongation on
the kinetics of Ab peptide fibrillar aggregation, we monitored
the temporal development of ThT fluorescence in Abx–40 and
Abx–42 peptide variants in a real-time manner. At a low peptide
concentration of roughly 10 mm, incubation in mild aggrega-
tion conditions (room temperature, with agitation) resulted in
a gradual increase in the ThT fluorescence intensities of all
studied Ab peptide variants (Figure 6). Table 4 summarizes the
kinetic parameters obtained from the analysis of the ThT traces
according to a logistic model.[26,30] The rate constants suggest
that the N-terminal extension by three residues promoted the
fibrillar aggregation of Ab40 and Ab42. It should, however, be
noted that the fluorescence signal intensities of Ab¢3–40 (2) fre-
quently rose to the maximum detection limit of the fluorime-
ter, hence precluding a reliable quantitative analysis of its ag-
gregation curves. Furthermore, the comparison of the aggrega-
tion kinetics between Ab1–42 and Ab¢3–42 (3) was complicated
by the presence of preformed aggregates in Ab1–42 samples as
indicated by the relatively high ThT intensities at initial time
points.
For further insight into the kinetics of Ab peptide aggrega-
tion, we measured the rate of monomer loss during Ab pep-
tide aggregation within the NMR tube (37 8C, without agita-
Figure 4. Fibrillar b-sheet-rich aggregation of Ab peptides as followed by
a thioflavin T (ThT) fluorescence assay. All three N-terminally elongated var-
iants of Ab peptides show a high rate and degree of ThT-reactive aggrega-
tion. Error bars represent one standard deviation of three measurements of
separately aggregated samples.
Figure 5. Electron microscopic images of the Ab peptides 1–3 and Ab1–42
after 24 h incubation under aggregation-prone conditions (37 8C, gentle stir-
ring) reveals their ability to form amyloid fibrils.
Figure 6. Real-time monitoring of thioflavin T (ThT) fluorescence during Ab
peptide incubation under aggregation-prone conditions (RT, 10 mm of Ab
peptide, gentle stirring). The N-terminally elongated variants of Ab peptide
(2 and 3) showed accelerated aggregation when compared to their corre-
sponding Ab1–x peptide analogues. Averages of three separate ThT traces
are shown, except of Ab¢3–40 (2) for which the ThT intensity in all but one
trace quickly rose to the maximum detection limit of the fluorimeter.
Table 4. Kinetic parameters of Ab peptide fibrillar aggregation obtained
from analysis of the time-dependent increase in ThT fluorescence intensi-
ties.[a,b]
F0 [a.u.] t1/2 [h] k [10
¢4 (a.u.)¢1h¢1] Flim [a.u.]
Ab1–40 5816 8.60.5 5.81.3 26781
Ab¢3–40 122 4.3 25.9 293
Ab1–42 35113 –[c] 2.00.3 5036
Ab¢3–42 261 3.10.2 21.010.8 509361
[a] F0 and Flim denote the initial and final fluorescence intensities; t1/2 rep-
resents the time for Ab peptide samples to reach half of their final ThT
fluorescence intensities ; k denotes a second-order rate constant govern-
ing the growth of ThT-reactive aggregates according to the equation: dF/
dt=kF (Flim¢F). [b] The errors represent the standard deviation of tripli-
cate aggregation experiments. [c] For Ab1–42, t1/2 was not determined
since the initial fluorescence level (F0) was already higher than half of the
final level (Flim).
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tion). The aggregation reaction was initiated by addition of ag-
gregation seeds, which were prepared from a mixture of amy-
loid aggregates from the Ab peptide variants under investiga-
tion. The highest rates of monomer loss were observed for
Ab¢3–42 (3) and Ab1–42, followed by Ab¢3–38 (1) and then by
Ab¢3–40 (2) and Ab1–40 (Figure 7). The comparison of the mono-
mer-consumption profiles, especially in the initial parts, sug-
gests that the N-terminal extension of Ab peptides by three
residues did not have any significant impact on the monomer-
incorporation rates into previously formed aggregates. More
rigorous kinetic experiments are, however, required before this
conclusion can be confirmed.
Taken together, our data indicate that N-terminally elongat-
ed Ab peptides (1–3) are disordered in solution and rapidly
form b-sheet-rich fibrillar aggregates. From the comparison of
Ab¢3–x with Ab1–x we suggest that N-terminal elongation in-
creases the propensity for aggregation, although the monomer
incorporation rate to preformed aggregates does not seem to
be significantly affected. This is in apparent contrast with
a very recent study, in which the impact of N-terminal elonga-
tion, ranging from 5–40 amino acids in length, on the aggrega-
tion kinetics of recombinant variants of human Ab42 was inves-
tigated.[31] All of the N-terminally extended forms of Ab42 under
investigation were shown to be able to form amyloid fibrils
similar to those formed from Ab1–42, but with lower rates. The
apparent discrepancy between these two studies may result
from differences in experimental procedures such as solubiliza-
tion of Ab peptide prior to aggregation assays or the different
lengths of the N-terminal extensions.
Six years ago, we reported that treatment of SH-SY5Y cells
overexpressing wild type human APP with membrane-anch-
ored tripartite BACE1 inhibitors reduced the overall cellular
generation of Ab peptide, but at the same time led to a relative
increase in specific Ab peptide variants displaying isoelectric
points (pI) different from that of known Ab peptides starting
with Asp(1), that is, pI of approximately 5.4 according to 2D-
Western blot analysis.[32] Mass spectrometry data indicated that
the BACE1-inhibitor-resistant Ab peptides comprise primarily
N-truncated peptides starting with Arg(5), and have a pI of ap-
proximately 6.5 according to a novel capillary isoelectric-focus-
ing (CIEF) immunoassay.[16,18,33–35] In addition, a minor fraction
of BACE1-inhibitor-resistant Ab peptides with a pI of approxi-
mately 6.0 was observed in supernatants of APP overexpress-
ing SH-SY5Y cells (see Figure 2 in ref. [18]). Although Ab2–40/
Ab3–40 were the most obvious candidates on the basis of their
predicted isoelectric points, no evidence for the presence of
such N-terminally truncated peptides was found using immu-
noprecipitation followed by mass spectrometry.[18] However,
when considering the occurrence of N-terminally elongated Ab
variants we could now assign prominent signals to Ab¢3–38 (1)
and Ab¢3–40 (2), and identify the latter as the main constituent
of the minor fraction of BACE1-inhibitor-resistant Ab peptides
in the SH-SY5Y cell supernatant (Figure 8). Given that Ab2–40/
Ab3–40 and Ab¢3–40 (2) have a virtually identical predicted iso-
electric point, the question arose whether these two Ab classes
can be separated by isoelectric-focusing techniques. The avail-
ability of synthetic Ab¢3–40 (2) enabled us to directly compare
the isoelectric points of Ab1–40, Ab2–40, and Ab¢3–40 (2) by CIEF
immunoassay (Figure 9). Most importantly, N-terminally elon-
gated Ab¢3–40 (2) can be resolved from N-terminally truncated
Ab2–40 by isoelectric focusing due to subtle differences in net
charge, providing a powerful tool to distinguish these two Ab
classes of biological and potentially pathological relevance.
Conclusion
We have developed an experimental procedure for the selec-
tive synthesis of the N-terminally elongated Ab peptides
Ab¢3–38 (1), Ab¢3–40 (2), and Ab¢3–42 (3). In depth biophysical
characterization indicated that all three elongated peptides are
prone to aggregate into thioflavin T-positive amyloid fibrils.
The cellular production from APP appears to occur indepen-
dently of BACE1 activity in transfected SH-SY5Y cells. Given
their occurrence in blood, the elongated Ab peptides starting
at Val(¢3) may have relevance in the context of biomarker re-
search. It is expected that the synthetic availability of these Ab
variants will advance the characterization of their potential
roles under physiological or pathological conditions.
Experimental Section
Experimental procedure for the synthesis of the peptides 1–3 :
The Ab peptides were prepared by Fmoc solid-phase peptide syn-
thesis using an ABI 433A peptide synthesizer with UV-detector.
Wang resin (NovaPEG Wang resin, 0.62 mmolg¢1, Novabiochem)
was used as solid support, HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate) as activation agent, and
piperidine for deprotection. The resin (Wang linker on polyethylene
glycol, 0.1 mmol, Novabiochem) was manually loaded with the first
amino acid using MSNT (1-(mesitylene-2-sulfonyl)-3-nitro-1,2,4-tria-
zole) activation in order to prevent racemization.[36] For this pur-
pose, the amino acid (20 equiv compared to the resin) was dis-
solved in CH2Cl2 (6 mL) and THF (2–3 mL) under an argon atmos-
phere. 1-Methylimidazole (15 equiv compared to the resin) and fi-
Figure 7. NMR-based monitoring of Ab peptide-monomer consumption
during aggregation induced by addition of aggregation seeds (37 8C, with-
out agitation). The highest rates of Ab peptide-monomer loss were observed
in Abx–42 peptide variants. No significant differences were observed between
Ab1–42 and Ab¢3–42 (3) or Ab1–40 and Ab¢3–40 (2), especially in the initial parts
of the monomer-consumption profiles.
Chem. Eur. J. 2016, 22, 8685 – 8693 www.chemeurj.org Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim8690
Full Paper
nally MSNT (20 equiv compared to the resin) were added. This so-
lution was added to the resin and stirred gently for 4 h. The mix-
ture was transferred to the synthesizer, in which washing with
CH2Cl2 and NMP was done. Then, acetylation of potentially free N-
terminal groups at the resin was achieved by treatment with Ac2O/
iPr2NEt in NMP. For the assembly of the peptide standard cycles
were used with the exception of coupling times, which were in-
creased from 15 min to 35 min and for some amino acids to
50 min (see below). For the synthesis of the peptides 1–3, a twofold
coupling was executed for Ser(26) and Ala(30). For the following
amino acids extended coupling times of 50 min were applied:
Ala(2), Glu(3), Phe(4), Arg(5), His(6), His(14), Gln(15), Lys(16),
Leu(17), Val(18), Phe(19), Asp(23), Val(24), Gly(25), Ser(26) (with two-
fold coupling), Asn(27), Lys(28), Gly(29), Ala(30) (with twofold cou-
pling), Ile(31), Ile(32), Gly(33), and Leu(34). After drying in vacuo,
the peptide was cleaved from the resin with TFA/1,2-ethanedithiol/
H2O/iPr3Si-H (95:2:2:1) at room temperature for 90 min. For Ab¢3–42
(3), some of the peptide already precipitated on treatment with
the cleavage reagent. The resin was removed by filtration and the
peptide precipitated in MeOtBu at ¢78 8C. The resulting white
solid was collected by twofold centrifugation (the solution from
first centrifugation was centrifuged a second time). The peptides
were dissolved in H2O with 0.1% TFA [for Ab¢3–38 (1) and Ab¢3–40
(2)] or hexafluoroisopropanol [for Ab¢3–42 (3)] and subsequently pu-
rified by preparative HPLC (Varian PrepStar system, with Varian
ProStar Model 320 UV and an evaporative light-scattering detector,
ELS 1000, Polymer Laboratories; column: reversed phase C8, 30Õ
250 mm, Vydac 208TP1030; flow rate: 20 mLmin¢1) using H2O with
Figure 8. Mass-spectrometric identification of the Ab peptides immunoprecipitated from cell-culture supernatants (SH-SY5Y cells overexpressing APPwt). A)
Without BACE1 inhibition (0.1% DMSO as vehicle control). B) After treatment with 100 nm of a prototypic tripartite BACE1 inhibitor (compound 8g in
ref. [32a]) for 72 h. The Ab peptides were immunoprecipitated from the conditioned media and analyzed by MALDI-MS. The inset shows the signal assigned
to Ab¢3–40 (2) in isotopic resolution, resulting in an accurate mass determination with only 108 ppm relative mass error (observed mass:
[M+H]+obsd=4685.852; calcd. mass: [M+H]
+
calcd=4686.360).
Figure 9. Comparison of the isoelectric points of the synthetic Ab peptides
Ab1–40, Ab2–40, and Ab¢3–40 (2) by CIEF immunoassay. Starting from stock solu-
tions in DMSO (1 mgmL¢1), the indicated Ab peptides were prediluted with
20 mm bicine buffer (pH 7.6, 0.6% CHAPS) and analyzed by CIEF immunoas-
say as described previously.[18] The final concentrations of the Ab peptides in
the microcapillaries were 25 ngmL¢1, each. The immunological detection
was achieved with monoclonal anti-Ab antibody WO-2 (Millipore) in combi-
nation with biotinylated anti-mouse secondary antibody and streptavidin-
coupled horseradish peroxidase (ProteinSimple). The electropherograms
shown (baseline-corrected signals) were recorded with 30 s of exposure
time.
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0.1% TFA as eluent A and MeCN with 0.1% TFA as eluent B. For
1 and 2, a gradient of 20% to 45% of eluent B over a period of
20 min afforded the peptides Ab¢3–38 (1) (25.5 mg, 5.7 mmol, 5.7%)
and Ab¢3–40 (2) (22.1 mg, 4.7 mmol, 4.7%) as colorless amorphous
solids after lyophilization. For 3, a gradient of 60% to 90% of
eluent B over a period of 20 min afforded the peptide Ab¢3–42 (3)
(16.3 mg, 3.3 mmol, 3.3%) as colorless amorphous solid after lyophi-
lization. The purity of the peptides was confirmed by analytical
HPLC (Agilent Model 1100 with G1315B UV-DAD and evaporative
light-scattering detector, ELS 1000, Polymer Laboratories; column:
reversed phase C8, 4.6Õ250 mm, Vydac 208TP104; flow rate:
1.0 mLmin¢1). Analysis was performed with H2O with 0.1% TFA as
eluent A and MeCN with 0.1% TFA as eluent B using a gradient of
20% to 50% of eluent B over a period of 30 min for Ab¢3–38 (1) and
Ab¢3–40 (2). For Ab¢3–42 (3), a gradient of 60% to 90% of eluent B
was used over a period of 30 min. The identity of the products was
confirmed by HR-MS (LTQ ORBITRAP XL, ThermoScientific) at a reso-
lution of 60000 and a mass accuracy of 3 ppm (see Supporting In-
formation).
Preparation of monomeric Ab peptide samples : To dissociate
preformed aggregates, the Ab peptide powders were dissolved in
20 mm NaOH at 2 mgmL¢1 peptide concentration and sonicated
for 1 min.[37] After shaking for 30 min at 4 8C, the Ab peptide solu-
tions were exposed to ultracentrifugation (100000 g, 4 8C, 1 h).
Subsequently, the supernatants were aliquoted, flash-frozen by
liquid nitrogen, and stored at ¢80 8C until use. Ab1–42 was pur-
chased from Peptide Specialty Laboratories (PSL) (Heidelberg, Ger-
many) with a purity of more than 95%.
NMR spectroscopy : NMR measurements were performed on
a 600 MHz Bruker spectrometer equipped with a cryogenic probe.
NMR samples contained 0.25 mgmL¢1 Ab in 20 mm sodium phos-
phate (pH 7.4) plus 100 mm DSS (4,4-dimethyl-4-silapentane-1-sul-
fonic acid) for chemical shift referencing (0 ppm). 2D-1H,1H-TOCSY
and NOESY spectra were obtained at 5 8C using mixing times of 60
and 80 ms for TOCSY and 200 and 300 ms for NOESY experiments.
Peak assignments were made through standard homonuclear se-
quential-assignment strategy. The PFG-NMR experiments were
measured at 5 8C as described previously.[21] Translational diffusion
coefficients, obtained after gradient calibration,[21] were converted
to hydrodynamic radii according to the Stokes–Einstein equation.
The hydrodynamic radius of dioxane was used for the viscosity cor-
rection. For NMR-based monomer-consumption assays, 1D-1H spec-
tra were measured before and after 24 h of incubation under ag-
gregation-prone conditions (37 8C, gentle stirring). The residual Ab
monomer levels were quantified on the basis of NMR-signal inten-
sities in the methyl region using DSS as internal intensity reference.
For real-time monitoring of Ab monomer consumption, seeds of
aggregation were added to 0.2 mgmL¢1 Ab samples (pH 7.4, buf-
fered with 50 mm sodium phosphate, containing 50 mm NaCl and
500 mm DSS), then consecutive 1D-1H spectra were measured at
regular intervals, while the Ab samples were incubated at 37 8C
within the NMR spectrometer. The aggregation seeds were pre-
pared after mixing the aggregated samples of Ab¢3–38 (1), Ab1–40,
Ab¢3–40 (2), Ab1–42, and Ab¢3–42 (3), spinning down the fibrils
(100000 g, 15 8C, 4 h), and sonication of resuspended Ab fibrils for
30 min. The concentration ratio of seed to monomeric Ab was
smaller than 1%.
Circular dichroism : CD measurements were performed on a J-815
JASCO spectropolarimeter using a cuvette of 1 mm path length.
Before and after 24 h of incubation under aggregation-prone con-
ditions (37 8C, gentle stirring), the CD spectra of Ab samples
(0.2 mgmL¢1, pH 7.4 buffered with 20 mm sodium phosphate)
were recorded at 20 8C between 190 and 260 nm.
Thioflavin T (ThT) aggregation assay : Ab samples (0.2 mgmL¢1,
pH 7.4 buffered with 20 mm sodium phosphate) were incubated
under aggregation-prone conditions (37 8C, gentle stirring). Before
and after the specified time points of incubation, the ThT assays
were performed by mixing 10 mL aliquots of the Ab samples with
2 mL ThT solution (5 mm, pH 8.0 buffered with 50 mm glycine).
Fluorescence emission spectra were measured using a Cary Eclipse
fluorescence spectrophotometer. The excitation wavelength was
446 nm and the ThT emission intensities were averaged between
478 and 488 nm. For the kinetic experiments presented in Figure 6,
Ab samples (0.04 mgmL¢1 in PBS, containing 25 mm ThT) were in-
cubated in mild aggregation conditions (RT, gentle stirring) and de-
velopment of the ThT fluorescence was followed in a real-time
manner with the excitation and emission wavelengths of 446 and
482 nm and slits of 10 nm. Aggregation experiments were con-
ducted in triplicate. The analysis of each ThT trace was performed
according to the equation: dF/dt=kF (Flim¢F).[26,30]
Electron microscopy : Ab samples (0.2 mgmL¢1, pH 7.4 buffered
with 25 mm HEPES) were incubated at 37 8C with gentle stirring.
After 24 h of incubation, samples were deposited onto carbon-
coated copper mesh grids and negatively stained with 2% (w/v)
uranyl acetate. The samples were examined using a Philips CM 120
BioTwin transmission electron microscope (Philips Inc. Eindhoven,
The Netherlands).
Cell culture, inhibitor treatment and Ab-immunoprecipitation :
Cultivation of transfected SH-SY5Y cells overexpressing human
wild-type APP695 with an amino-terminal Myc tag and a carboxy-
terminal Flag tag and treatment with a prototypic tripartite BACE1
inhibitor (compound 8g in ref. [32a]) were described previously.[32a]
After 72 h of treatment with 100 nm of tripartite inhibitor or 0.1%
DMSO (vehicle control), the conditioned media were collected and
the Ab peptides immunoprecipitated as described previously.[18, 32a]
A volume of 800 mL of cell-culture supernatant was mixed briefly
with 200 mL of a 5X IP-detergent buffer (250 mm HEPES/NaOH,
pH 7.4), 750 mm NaCl, 2.5% (v/v) Nonidet P-40 (Igepal CA630),
1.25% (w/v) sodium deoxycholate, 0.25% (w/v) SDS) and incubat-
ed overnight at 4 8C under rotation with 25 mL of magnetic beads
(magnetic sheep-anti-mouse-IgG Dynabeads M-280 from Life Tech-
nologies, precoated with monoclonal anti-Ab antibody 6E10, Cova-
nce). The immobilized immune complexes were collected on
a magnetic stand and washed 2Õ5 min with PBS, 2Õ5 min with
50 mm NH4HCO3 and once with ultrapure H2O. For MALDI-MS anal-
ysis the immunoprecipitated Ab peptides were eluted for 5 min in
50 mL of 0.1% HCHO/0.05% n-octyl b-d-glucopyranoside (OGP) at
RT.
Mass spectrometry : The masses of the intact Ab peptides were
determined as described previously.[18] In a vacuum centrifuge, the
volume of the eluted fraction from immunoprecipitation was re-
duced to about 10 mL and 0.3 mL were spotted onto an Anchor-
Chip target (Bruker Daltonics, Bremen, Germany) precoated with 2-
cyano-4-hydroxycinnamic acid. After drying, the samples were
washed twice with (NH4)H2PO4 (10 mm in 0.1% TFA) and analyzed
by mass spectrometry using an Ultraflex MALDI TOF/TOF instru-
ment (Bruker Daltonics, Bremen, Germany) as described previous-
ly.[13, 18]
Isoelectric point determination by the CIEF-Immunoassay: The
isoelectric point (pI) of the peptide Ab¢3–40 (2) was compared to
those of Ab1–40 and Ab2–40 (Ana Spec Inc. , Fremont CA) by capillary
isoelectric-focusing immunoassay (CIEF immunoassay) on a Nano-
Pro 1000 device (Protein Simple) according to a reported proce-
dure.[18] The immunological detection shown in Figure 7 was
achieved with monoclonal anti-Ab antibody WO-2 (Millipore) with
a 1:50 dilution in combination with biotinylated goat-anti-mouse
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secondary antibody (1:100) and streptavidin-coupled horseradish
peroxidase (1:100) (Protein Simple).
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